OrthoPediatrics (NASDAQ:KIDS) Earns "Buy" Rating from Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of OrthoPediatrics (NASDAQ:KIDS - Free Report) in a research report report published on Friday morning,Benzinga reports. They currently have a $42.00 price objective on the stock.

KIDS has been the subject of a number of other reports. Truist Financial decreased their price objective on shares of OrthoPediatrics from $34.00 to $28.00 and set a "hold" rating for the company in a research report on Monday, October 14th. JMP Securities reissued a "market outperform" rating and issued a $50.00 price objective on shares of OrthoPediatrics in a research report on Friday, September 13th.

OrthoPediatrics Stock Down 6.4 %

NASDAQ:KIDS traded down $1.77 on Friday, reaching $25.72. The stock had a trading volume of 367,369 shares, compared to its average volume of 166,985. The company has a current ratio of 4.90, a quick ratio of 1.96 and a debt-to-equity ratio of 0.03. The company has a 50-day moving average of $27.89 and a 200 day moving average of $29.84. The stock has a market cap of $622.68 million, a P/E ratio of -25.22 and a beta of 1.16. OrthoPediatrics has a 12-month low of $24.02 and a 12-month high of $36.23.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last posted its quarterly earnings data on Monday, August 5th. The company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.08. The company had revenue of $52.80 million during the quarter, compared to analysts' expectations of $52.40 million. OrthoPediatrics had a negative net margin of 14.35% and a negative return on equity of 5.44%. On average, research analysts predict that OrthoPediatrics will post -0.92 earnings per share for the current year.

Insider Transactions at OrthoPediatrics

In other news, General Counsel Daniel J. Gerritzen sold 10,000 shares of the stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $29.30, for a total transaction of $293,000.00. Following the transaction, the general counsel now owns 77,304 shares of the company's stock, valued at approximately $2,265,007.20. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 31.80% of the company's stock.

Hedge Funds Weigh In On OrthoPediatrics

Several large investors have recently modified their holdings of the stock. BNP Paribas Financial Markets raised its stake in OrthoPediatrics by 85.1% during the first quarter. BNP Paribas Financial Markets now owns 12,414 shares of the company's stock worth $362,000 after acquiring an additional 5,707 shares during the period. Quantbot Technologies LP raised its stake in OrthoPediatrics by 180.8% during the first quarter. Quantbot Technologies LP now owns 7,091 shares of the company's stock worth $207,000 after acquiring an additional 4,566 shares during the period. State Board of Administration of Florida Retirement System acquired a new stake in OrthoPediatrics during the first quarter worth about $178,000. Vanguard Group Inc. raised its stake in OrthoPediatrics by 1.3% during the first quarter. Vanguard Group Inc. now owns 883,827 shares of the company's stock worth $25,772,000 after acquiring an additional 11,100 shares during the period. Finally, EntryPoint Capital LLC raised its stake in OrthoPediatrics by 56.9% during the first quarter. EntryPoint Capital LLC now owns 2,783 shares of the company's stock worth $81,000 after acquiring an additional 1,009 shares during the period. Institutional investors own 69.05% of the company's stock.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.